Curriculum vitae PD Dr. Matthias Brendel

Training

• 2008 - 2014 Medical School, LMU Munich
• 2011 - 2015 Medical thesis at the Department of Nuclear Medicine, LMU Munich, Germany (summa cum laude)
• 2016 - 2018 Master of Health Business Administration (MHBA), University of Nuremberg-Erlangen, Nuremberg, Germany
• 2020 Board certification in Nuclear medicine, Government of Upper Bavaria

Academic positions & appointments

• since 2018 Group leader for molecular imaging of neurodegenerative diseases
• 2021 Habilitation on the topic “Molecular imaging of microglia in mouse models of neurodegenerative diseases”, LMU Munich (Nuclear Medicine)
• since 2021 Deputy head, Department of Nuclear Medicine, LMU Munich, Germany

Membership in Editorial Boards

• since 2020 Member of the Editorial Board of EJNMMI

Awards & honors

• 2013 DAAD Conference Fellowship, EANM 2013, Lyon, Fran
• 2014 Brain Imaging Council Young Investigator Award (2nd price), Society of Nuclear Medicine and Molecular Imaging, Annual Meeting, St. Louis, USA
• 2015 Brain Imaging Council Young Investigator Award (1st price), Society of Nuclear Medicine and Molecular Imaging, Annual Meeting, Baltimore, USA
• 2015 - 2019 Alavi-Mandell Publication Award, Society of Nuclear Medicine and Molecular Imaging (4x)
• 2015 Steinberg-Krupp Alzheimer’s disease Award 2015. German Hirnliga e.V.
• 2015 Dr. Hildegard und Heinrich Fuchs Thesis Award of the Medical Faculty, LMU Munich, Germany
• 2016 Promotion Award for Imaging, German Society of Nuclear Medicine, Dresden, Germany
• 2018 Young Investigator Award, German Society of Nuclear Medicine, Bremen, Germany
• 2018 - 2019 Manfred-Strohscheer Fellowship, German Hirnliga e.V.
• 2019 Brain Imaging Council Young Investigator Award (1st price), Society of Nuclear Medicine and Molecular Imaging, Annual Meeting, Anaheim, USA
• 2019 Best Basic Science Paper Award, Journal of Nuclear Medicine
• 2020 Travel award, Human Amyloid Imaging Conference, Miami, USA

10 key publications

• Shi Y, Cui M, Ochs K, Brendel M, Strübing FL, Briel N, Eckenweber F, Zou C, Banati RB, Liu GJ, Middleton RJ, Rupprecht R, Rudolph U, Zeilhofer HU, Rammes G, Herms J, Dorostkar MM (2022) Translocator protein (18 kDa) TSPO: Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial. Nat Neurosci (in press)
• Franzmeier N, Brendel M, Beyer L, Sleman L, Kovacs G, Arzberger T, Kurz C, Respondek G, Lukic MJ, Biel D, Rubinski A, Frontzkowski L, Hummel S, Finze A, Palleis C, Joseph E, Weidinger E, Katzdobler S, Song M, Biechele G, Kern M, Scheifele M, Rauchmann B-S, Perneczky R, Rullman M, Patt M, Schildan A, Barthel H, Sabri O, Rumpf JJ, Schroeter ML, Classen J, Villemagne V, Seybl J, Stephens AW, Lee EB, Coughlin DG, Giese A, Grossman M, McMillan CT, Gelpi E, Molina-Porcel L, Compta Y, van Swieten JC, Laat LD, Troakes C, Al-Sarraj S, Robinson JL, Xie SX, Irwin DJ, Roeber S, Herms J, Simons M, Bartenstein P, Lee VM, Trojanowski JQ, Levin J, Höglinger GU, Ewers M (2022) Tau deposition patterns are associated with functional connectivity in primary tauopathies – evidence from tau-PET and histopathology. Nat Commun (in press)
• Xiang X, Wind K, Wiedemann T, Blume T, Shi Y, Briel N, Beyer L, Biechele G, Eckenweber F, Zatcepin A, Lammich S, Ribicic S, Tahirovic S, Willem M, Deussing M, Palleis C, Rauchmann B, Gildehaus F, Lindner S, Spitz C, Franzmeier FJ, Baumann K, Rominger A, Bartenstein P, Ziegler S, Drzezga A, Respondek G, Buerger K, Perneczky R, Levin J, Höglinger G, Herms J, Haass C, Brendel M (2021) Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci Transl Med 13: eabe5640
• Neitzel J, Franzmeier N, Rubinski A, Dichgans M, Brendel M (2021) ADNI Alzheimer’s Disease Neuroimaging Initiative Malik R, Ewers M KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease. Nat Commun 12: 3825
• Franzmeier N, Ossenkoppele R, Brendel M, Rubinski A, Smith R, Kumar A, Mattsson-Carlgren N, Strandberg O, Duering M, Buerger K, Dichgans M, Hansson O, Ewers M (2021) The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline. Alzheimers Dement 18: 103-115
• Biechele G, Sebastian Monasor L, Wind K, Blume T, Parhizkar S, Arzberger T, Sacher C, Beyer L, Eckenweber F, Gildehaus FJ, von Ungern-Sternberg B, Willem M, Bartenstein P, Cumming P, Rominger A, Herms J, Lichtenthaler SF, Haass C, Tahirovic S, Brendel M (2021) Glitter in the Darkness? Non-fibrillar β-amyloid Plaque Components Significantly Impact the β-amyloid PET Signal in Mouse Models of Alzheimer’s Disease. J Nucl Med 63: 117-124
• Palleis C, Sauerbeck J, Beyer L, Harris, S, Schmitt J, Morenas-Rodriguez E, Finze A, Nitschmann A, Ruch-Rubinstein F, Eckenweber F, Biechele G, Blume T, Shi Y, Weidinger E, Prix C, Bötzel K, Danek A, Rauchmann B-S, Stöcklein S, Lindner S, Unterrainer M, Albert NL, Wetzel C, Rupprecht R, Rominger A, Bartenstein P, Herms J, Perneczky R, Haass C, Levin J, Höglinger GU, Brendel M (2021) In vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies. Mov Disord 36: 883-894
• Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, Palleis C, Gehmeyr M, Fietzek U, Respondek G, Sauerbeck J, Nitschmann A, Zach C, Hammes J, Barbe MT, Onur O, Jessen F, Saur D, Schroeter ML, Rumpf J, Rullmann M, Schildan A, Patt M, Neumaier B, Barret O Madonia J, Russell DS, Stephens A, Roeber S, Herms J, Bötzel K, Classen J, Bartenstein P, Villemagne VL, Levin J, Höglinger GU, Drzezga A, Seibyl J (2020) Sabri, O. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol 77: 1408-1419
• Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Müller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Ertürk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C (2019) Loss of TREM2 function increases amyloid seeding but reduces plaque associated ApoE. Nat Neurosci 22: 191-204
• Brendel M, Jaworska A, Herms J, Trambauer J, Rotzer C, Gildehaus FJ, Carlsen J, Cumming P, Bylund J, Luebbers T, Bartenstein P, Steiner H, Haass C, Baumann K, Rominger A (2015) Amyloid-PET predicts inhibition of de novo plaque formation upon chronic gamma-secretase modulator treatment. Mol Psychiatry 20: 1179-1187